Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Commentary

Early Investigations of 20-kDa Human Placental GH Show Promise

Author(s): Edward O. List*, Darlene E. Berryman, Brian P. List and John J. Kopchick

Volume 23, Issue 13, 2023

Published on: 15 June, 2023

Page: [1674 - 1677] Pages: 4

DOI: 10.2174/1871530323666230515153130

« Previous
Graphical Abstract

[1]
Houssay BA, Biasotti A. The hypothesis, carbohydrate metabolism and diabetes. Endocrinology 1931; 15(6): 511-23.
[http://dx.doi.org/10.1210/endo-15-6-511]
[2]
Houssay BA. The hypophysis and metabolism. N Engl J Med 1936; 214(20): 961-71.
[http://dx.doi.org/10.1056/NEJM193605142142001]
[3]
Rabinowitz D, Klassen GA, Zierler KL. Effect of human growth hormone on muscle and adipose tissue metabolism in the forearm of man. J Clin Invest 1965; 44(1): 51-61.
[http://dx.doi.org/10.1172/JCI105126] [PMID: 14254256]
[4]
Rabinowitz D, Zierler KL. A metabolic regulating device based on the actions of human growth hormone and of insulin, singly and to-gether, on the human forearm. Nature 1963; 199(4896): 913-5.
[http://dx.doi.org/10.1038/199913a0] [PMID: 14079908]
[5]
Luft R, Cerasi E. Human growth hormone as a regulator of blood glucose concentration and as a diabetogenic substance. Diabetologia 1968; 4(1): 1-9.
[http://dx.doi.org/10.1007/BF01241026] [PMID: 5741523]
[6]
Bornstein J, Armstrong JM, Gould MK, Harcourt JA, Jones MD. Mechanism of the diabetogenic action of growth hormone I. Effect of polypeptides derived from growth hormone on glycolysis in muscle. Biochim Biophys Acta, Gen Subj 1969; 192(2): 265-70.
[http://dx.doi.org/10.1016/0304-4165(69)90364-X] [PMID: 5370020]
[7]
Lostroh AJ. Diabetogenic hormones (human choriosomatomammotrophin and ovine growth hormone): anti-insulin action in hypophysec-tomized rats. Eur J Endocrinol 1974; 77(1): 96-102.
[http://dx.doi.org/10.1530/acta.0.0770096] [PMID: 4408181]
[8]
Cameron CM, Kostyo JL. Influence of age on responsiveness to diabetogenic action of growth hormone. Diabetes 1987; 36(1): 88-92.
[http://dx.doi.org/10.2337/diab.36.1.88] [PMID: 3539676]
[9]
Jørgensen JOL, Møller N, Lauritzen T, Alberti KGMM, Ørskov H, Christiansen JS. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: Effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab 1990; 70(1): 207-14.
[http://dx.doi.org/10.1210/jcem-70-1-207] [PMID: 2294131]
[10]
Krusenstjerna-Hafstrøm T, Clasen BF, Møller N, et al. Growth hormone (GH)-induced insulin resistance is rapidly reversible: An experimental study in GH-deficient adults. J Clin Endocrinol Metab 2011; 96(8): 2548-57.
[http://dx.doi.org/10.1210/jc.2011-0273] [PMID: 21613350]
[11]
Dal J, List EO, Jørgensen JOL, Berryman DE. Glucose and fat metabolism in acromegaly: From mice models to patient care. Neuroendocrinology 2016; 103(1): 96-105.
[http://dx.doi.org/10.1159/000430819] [PMID: 25925240]
[12]
Miller WL, Eberhardt NL. Structure and evolution of the growth hormone gene family. Endocr Rev 1983; 4(2): 97-130.
[http://dx.doi.org/10.1210/edrv-4-2-97] [PMID: 6345149]
[13]
Solomon G, Reicher S, Gussakovsky EE, Jomain JB, Gertler A. Large-scale preparation and in vitro characterization of biologically active human placental (20 and 22K) and pituitary (20K) growth hormones: Placental growth hormones have no lactogenic activity in hu-mans. Growth Horm IGF Res 2006; 16(5-6): 297-307.
[http://dx.doi.org/10.1016/j.ghir.2006.07.002] [PMID: 17010651]
[14]
Boguszewski CL, Svensson PA, Jansson T, Clark R, Carlsson LM, Carlsson B. Cloning of two novel growth hormone transcripts expressed in human placenta. J Clin Endocrinol Metab 1998; 83(8): 2878-85.
[http://dx.doi.org/10.1210/jc.83.8.2878] [PMID: 9709963]
[15]
Männik J, Vaas P, Rull K, Teesalu P, Rebane T, Laan M. Differential expression profile of growth hormone/chorionic somatomam-motropin genes in placenta of small- and large-for-gestational-age newborns. J Clin Endocrinol Metab 2010; 95(5): 2433-42.
[http://dx.doi.org/10.1210/jc.2010-0023] [PMID: 20233782]
[16]
Vickers MH, Gilmour S, Gertler A, et al. 20-kDa placental hGH-V has diminished diabetogenic and lactogenic activities compared with 22-kDa hGH-N while retaining antilipogenic activity. Am J Physiol Endocrinol Metab 2009; 297(3): E629-37.
[http://dx.doi.org/10.1152/ajpendo.00221.2009] [PMID: 19509186]
[17]
List EO, Berryman DE, Basu R, et al. The effects of 20-kDa human placental GH in male and female GH-deficient mice: An improved human GH? Endocrinology 2020; 161(8): bqaa097.
[http://dx.doi.org/10.1210/endocr/bqaa097] [PMID: 32556100]
[18]
Takahashi S, Shiga Y, Satozawa N, Hayakawa M. Diabetogenic activity of 20 kDa human growth hormone (20K-hGH) and 22K-hGH in rats. Growth Horm IGF Res 2001; 11(2): 110-6.
[http://dx.doi.org/10.1054/ghir.2001.0198] [PMID: 11472077]
[19]
Ishikawa M, Tachibana T, Kamioka T, Horikawa R, Katsumata N, Tanaka T. Comparison of the somatogenic action of 20kDa- and 22kDa-human growth hormones in spontaneous dwarf rats. Growth Horm IGF Res 2000; 10(4): 199-206.
[http://dx.doi.org/10.1054/ghir.2000.0153] [PMID: 11032703]
[20]
Ishikawa M, Hiroi N, Kamioka T, et al. Metabolic effects of 20 kDa and 22 kDa human growth hormones on adult male spontaneous dwarf rats. Eur J Endocrinol 2001; 145(6): 791-7.
[http://dx.doi.org/10.1530/eje.0.1450791] [PMID: 11720906]
[21]
Lewis UJ, Singh RNP, Tutwiler GF. Hyperglycemic activity of the 20,000-dalton variant of human growth hormone. Endocr Res Commun 1981; 8(3): 155-64.
[http://dx.doi.org/10.3109/07435808109045736] [PMID: 7037363]
[22]
Hayakawa M, Shimazaki Y, Tsushima T, et al. Metabolic effects of 20-kilodalton human growth hormone (20K-hGH) for adults with growth hormone deficiency: results of an exploratory uncontrolled multicenter clinical trial of 20K-hGH. J Clin Endocrinol Metab 2004; 89(4): 1562-71.
[http://dx.doi.org/10.1210/jc.2003-030716] [PMID: 15070913]
[23]
Kostyo JL, Cameron CM, Olson KC, Jones AJ, Pai RC. Biosynthetic 20-kilodalton methionyl-human growth hormone has diabeto-genic and insulin-like activities. Proc Natl Acad Sci USA 1985; 82(12): 4250-3.
[http://dx.doi.org/10.1073/pnas.82.12.4250] [PMID: 3889926]
[24]
Ader M, Agajanian T, Finegood DT, Bergman RN. Recombinant deoxyribonucleic acid-derived 22K- and 20K-human growth hor-mone generate equivalent diabetogenic effects during chronic infusion in dogs. Endocrinology 1987; 120(2): 725-31.
[http://dx.doi.org/10.1210/endo-120-2-725] [PMID: 3542508]
[25]
Jacobson EM, Hugo ER, Tuttle TR, Papoian R, Ben-Jonathan N. Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor. Trends Endocrinol Metab 2010; 21(11): 691-8.
[http://dx.doi.org/10.1016/j.tem.2010.08.004] [PMID: 20846877]
[26]
Thomas LN, Merrimen J, Bell DG, Rendon R, Too CKL. Prolactin- and testosterone-induced carboxypeptidase-D correlates with increased nitrotyrosines and Ki67 in prostate cancer. Prostate 2015; 75(15): 1726-36.
[http://dx.doi.org/10.1002/pros.23054] [PMID: 26202060]
[27]
Wen Y, Zand B, Ozpolat B, et al. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 2014; 7(2): 488-500.
[http://dx.doi.org/10.1016/j.celrep.2014.03.009] [PMID: 24703838]
[28]
Levina VV, Nolen B, Su Y, et al. Biological significance of prolactin in gynecologic cancers. Cancer Res 2009; 69(12): 5226-33.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-4652] [PMID: 19491263]
[29]
Tan D, Chen KE, Khoo T, Walker AM. Prolactin increases survival and migration of ovarian cancer cells: Importance of prolactin receptor type and therapeutic potential of S179D and G129R receptor antagonists. Cancer Lett 2011; 310(1): 101-8.
[http://dx.doi.org/10.1016/j.canlet.2011.06.014] [PMID: 21775057]
[30]
Neradugomma NK, Subramaniam D, Tawfik OW, et al. Prolactin signaling enhances colon cancer stemness by modulating Notch signaling in a Jak2-STAT3/ERK manner. Carcinogenesis 2014; 35(4): 795-806.
[http://dx.doi.org/10.1093/carcin/bgt379] [PMID: 24265293]
[31]
Wennbo H, Törnell J. The role of prolactin and growth hormone in breast cancer. Oncogene 2000; 19(8): 1072-6.
[http://dx.doi.org/10.1038/sj.onc.1203349] [PMID: 10713692]
[32]
Subramani R, Nandy SB, Pedroza DA, Lakshmanaswamy R. Role of growth hormone in breast cancer. Endocrinology 2017; 158(6): 1543-55.
[http://dx.doi.org/10.1210/en.2016-1928] [PMID: 28379395]
[33]
Chatzistamou I, Schally AV, Varga JL, et al. Antagonists of growth hormone-releasing hor-mone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice. J Clin Endocrinol Metab 2001; 86(5): 2144-52.
[PMID: 11344219]
[34]
Melmed GY, Devlin SM, Vlotides G, et al. Anti-aging therapy with human growth hormone associat-ed with metastatic colon cancer in a patient with Crohn’s colitis. Clin Gastroenterol Hepatol 2008; 6(3): 360-3.
[http://dx.doi.org/10.1016/j.cgh.2007.12.017] [PMID: 18255351]
[35]
Wang Z, Prins GS, Coschigano KT, et al. Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse. Endocrinology 2005; 146(12): 5188-96.
[http://dx.doi.org/10.1210/en.2005-0607] [PMID: 16141391]
[36]
Xu J, Sun D, Jiang J, et al. The role of prolactin receptor in GH signaling in breast cancer cells. Mol Endocrinol 2013; 27(2): 266-79.
[http://dx.doi.org/10.1210/me.2012-1297] [PMID: 23192981]
[37]
Xu J, Zhang Y, Berry PA, et al. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex. Mol Endocrinol 2011; 25(4): 597-610.
[http://dx.doi.org/10.1210/me.2010-0255] [PMID: 21310852]

Rights & Permissions Print Cite
Article Metrics
24
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy